PRECISELY Targeted Therapies for patients with cancer
With deep expertise in chemistry and structure-based drug discovery, Nuvalent is creating precisely targeted therapies for patients with cancer.
We design innovative small molecules that precisely inhibit clinically proven kinase targets to solve for the dual challenges of resistance and selectivity.
We partner with physician-scientists to identify patient needs and the limitations of existing therapies.
We are passionate about using our expertise to address the needs of patients with cancer.







Tangpeerachaikul, PhD

Tangpeerachaikul, PhD







Analysis

Analysis




























Portfolio Management

Portfolio Management







Development

Development


Nuvalent Highlights Corporate and Pipeline Achievements and Reports Third Quarter 2023 Financial Results
Read More >Nuvalent to Participate in the BMO Virtual BioPharma Spotlight Series: Oncology Day
Read More >